Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics

Heart Failure Clinical Trial

— Alberta HEART  

Official title:

Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02052804
• Other study ID #: AHFMRITG200801018
• Status: Completed
• Start date: April 2009
• Est. completion date: May 2, 2022

Study information

• Verified date: May 2022
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objectives of this study are: 1) to design new diagnostic criteria used to accurately define heart failure with preserved ejection fraction (HFpEF); 2) to better define the risk factors associated with HFpEF; 3) to elucidate the clinical, cellular and molecular mechanisms involved with the development and progression of HFpEF; 4) to design and test new therapeutic strategies for patients with HFpEF.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 700
• Est. completion date: May 2, 2022
• Est. primary completion date: December 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Group 1 No clinically overt heart failure

• Group 2 Known coronary artery disease

• Group 3 Known heart failure with preserved ejection fraction

• Group 4 Known heart failure with reduced ejection fraction

• Group 5 Healthy age-matched controls

Exclusion Criteria:

• Age <18 years

• Known malignancy with expected survival <1 year

• Pregnant or recent pregnancy <6 months

• Recent event (<2 weeks since Acute Coronary Syndrome, Heart failure or other admission

• Severe mitral or aortic stenosis

Related Conditions & MeSH terms

• Heart Failure

Locations

Country	Name	City	State
Canada	University of Calgary	Calgary	Alberta
Canada	University of Alberta	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent of patients meeting new diagnostic criteria for HFpEF		Up to 5 years